Genetic Markers in Triple-Negative Breast Cancer

摘要: Triple-negative breast cancer (TNBC) accounts for 15% to 20% of cases and is characterized by the absence estrogen, progesterone, human epidermal growth factor 2 receptors. Though TNBC a highly heterogenic aggressive disease, patients have better response neoadjuvant therapy compared other subtypes. Nevertheless, with residual disease very poor prognosis, higher probability relapse lower overall survival in first years after diagnosis. has 6 subtypes distinct molecular signatures different prognoses probably responses therapy. The precise stratification therefore crucial development potent standardized targeted therapies. In spite intensive research into finding new biomarkers designing personalized therapeutic approaches, BRCA mutational status only clinically validated biomarker TNBC. Recent studies reported several promising that are currently being through clinical trials. objective this review was summarize relevant genetic markers could serve as diagnostic, prognostic, or predictive improve strategies.